Capital International Investors Portfolio holdings
Capital International, established in 1968 as a division of the Los Angeles-based Capital Group, is a global investment management firm focused on delivering equity investment solutions for institutional and individual clients worldwide. Operating as part of one of the oldest and largest asset managers, founded in 1931, it leverages Capital Group’s signature research-driven, long-term investment philosophy, managing billions in assets through a multi-manager system that diversifies risk and enhances performance. Headquartered in Los Angeles with a presence across North America, Europe, and Asia, Capital International specializes in international and global equity strategies, often through mutual funds like those in the American Funds family. Known for its rigorous fundamental analysis and commitment to client outcomes, it plays a key role in Capital Group’s mission to provide consistent, superior returns in global markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$2.74B |
| 2 |
Pfizer
PFE
|
+$1.94B |
| 3 |
Morgan Stanley
MS
|
+$1.75B |
| 4 |
Bristol-Myers Squibb
BMY
|
+$1.54B |
| 5 |
Constellation Energy
CEG
|
+$1.08B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$2.76B |
| 2 |
Exelon
EXC
|
+$2.22B |
| 3 |
Gilead Sciences
GILD
|
+$1.94B |
| 4 |
Union Pacific
UNP
|
+$1.55B |
| 5 |
Microsoft
MSFT
|
+$1.29B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.02% |
| 2 | Financials | 14.78% |
| 3 | Healthcare | 14.09% |
| 4 | Communication Services | 11.78% |
| 5 | Industrials | 8.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Air Products & Chemicals
APD
$67.7B
| $861M | 0.2% |
3,444,737
-2,966,384
| -46% | -$762M |
|
127
American International
AIG
$39.8B
| $860M | 0.2% |
13,699,746
-3,625,219
| -21% | -$218M |
|
128
Archer Daniels Midland
ADM
$38.4B
| $848M | 0.19% |
+9,389,631
| New | +$731M |
|
129
GSK
GSK
$101B
| $832M | 0.19% |
15,280,194
-14,387
| -0.1% | -$781K |
|
130
NVIDIA
NVDA
$5.43T
| $820M | 0.19% |
30,064,210
+8,869,690
| +42% | +$222M |
|
131
Enbridge
ENB
$112B
| $816M | 0.19% |
17,715,540
-122,861
| -0.7% | -$5.26M |
|
132
Mettler-Toledo International
MTD
$28.8B
| $813M | 0.19% |
591,960
+64,931
| +12% | +$93.7M |
|
133
TFI International
TFII
$12B
| $797M | 0.18% |
7,468,728
+691,617
| +10% | +$70.4M |
|
|
AVGOP
134
DELISTED
Broadcom Inc. 8.00% Mandatory Convertible Preferred Stock, Series A
AVGOP
| $794M | 0.18% |
404,382
+445
| +0.1% | +$821K |
|
135
Costco
COST
$421B
| $783M | 0.18% |
1,359,182
+1,814
| +0.1% | +$952K |
|
136
Equifax
EFX
$21.2B
| $774M | 0.18% |
3,262,935
-1,969,932
| -38% | -$464M |
|
|
HZNP
137
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $744M | 0.17% |
+7,075,657
| New | +$690M |
|
138
L3Harris
LHX
$54.1B
| $743M | 0.17% |
2,988,769
-2,951,751
| -50% | -$687M |
|
139
Brookfield
BN
$110B
| $729M | 0.17% |
23,914,378
-7,619,139
| -24% | -$228M |
|
140
ITT
ITT
$19.4B
| $727M | 0.17% |
9,667,022
-246,078
| -2% | -$21.7M |
|
141
CMS Energy
CMS
$22B
| $721M | 0.16% |
10,315,445
-1,202,925
| -10% | -$78M |
|
142
Zimmer Biomet
ZBH
$18.7B
| $721M | 0.16% |
5,638,192
-58,237
| -1% | -$7.02M |
|
143
Kraft Heinz
KHC
$29.1B
| $714M | 0.16% |
18,116,821
-295,541
| -2% | -$11.1M |
|
144
MKS Inc
MKSI
$20.7B
| $707M | 0.16% |
4,713,051
+1,850
| +0% | +$287K |
|
145
Bank of America
BAC
$453B
| $685M | 0.16% |
16,617,506
-13,770,858
| -45% | -$621M |
|
|
EA
146
DELISTED
Electronic Arts
EA
| $675M | 0.15% |
5,335,855
+122,171
| +2% | +$15.9M |
|
147
MSCI
MSCI
$40.9B
| $673M | 0.15% |
1,338,596
+127,820
| +11% | +$66.3M |
|
148
Strategy Inc
MSTR
$37.3B
| $672M | 0.15% |
13,824,630
+438,380
| +3% | +$19M |
|
|
ABB
149
DELISTED
ABB Ltd
ABB
| $667M | 0.15% |
20,576,757
+403,624
| +2% | +$14.1M |
|
150
Hormel Foods
HRL
$13.4B
| $654M | 0.15% |
12,690,309
-1,090,249
| -8% | -$53.4M |
|
Similar funds
Capital International Investors's Q1 2022 Portfolio in Review
As of Q1 2022, Capital International Investors held 493 positions worth $439B, down 7.3% from $473B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Capital International Investors's Q1 2022 filing shows 33 new, 208 increased, 177 reduced and 39 closed positions. Its largest new stake was Bristol-Myers Squibb: 22,900,931 shares worth $1.67B. The largest sale was Activision Blizzard, an estimated $2.76B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Healthcare.
- Capital International Investors's largest Q1 2022 buy was Bristol-Myers Squibb: 22,900,931 shares worth $1.67B.
- Capital International Investors added most to AbbVie in Q1 2022, an estimated $2.74B increase.
- Capital International Investors's biggest Q1 2022 reduction was Activision Blizzard, cutting an estimated $2.76B.
- Capital International Investors fully exited Athene Holding Ltd. Class A Common Shares in Q1 2022, selling an estimated $686M.
- Capital International Investors's ten largest holdings make up 27% of its $439B portfolio in Q1 2022.
- Capital International Investors opened 33 new positions and closed 39 in Q1 2022.
- Capital International Investors's portfolio value fell 7.3% quarter-over-quarter to $439B.
Based on Capital International Investors's 13F filing for Q1 2022, filed 16 May 2022.